BBOT (BBOT) COO Idan sees 343 shares withheld to cover RSU tax bill

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. reported a routine insider equity event for COO & Principal Financial Officer Elmelech Idan. The company withheld 343 shares of Common Stock at $7.80 per share to cover his tax obligations tied to vesting restricted stock units. This was a tax-withholding disposition, not an open-market trade, and reflects how part of his equity award was used to pay taxes. After this withholding, Idan directly holds 14,495 shares of the company’s common stock.

Insider Trade Summary

Net Seller: 343 shares

Net Sell 1 txn

Insider Elmelech Idan

Role COO & Principal Financial Ofcr

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	343	$7.80	$3K

Holdings After Transaction: Common Stock — 14,495 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

Key Figures

Shares withheld for taxes: 343 shares Withholding share value: $7.80 per share Shares held after transaction: 14,495 shares

3 metrics

Shares withheld for taxes 343 shares Withheld to satisfy tax obligations on RSU vesting

Withholding share value $7.80 per share Value used for tax-withholding disposition

Shares held after transaction 14,495 shares Direct holdings of Elmelech Idan following withholding

Key Terms

restricted stock units, tax withholding obligations, Common Stock

3 terms

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations"

Common Stock financial

"Represents the number of shares of the Issuer's Common Stock withheld"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/06/2026 - 06:01 PM Accepted by SEC EDGAR 07/06/2026 - 06:00 PM Learn about SEC filing dates

FAQ

What insider transaction did BBOT executive Elmelech Idan report on this Form 4?

The filing shows a tax-related share disposition, not a market sale. BridgeBio Oncology Therapeutics withheld 343 shares of common stock from COO Elmelech Idan to satisfy tax obligations on vesting restricted stock units.

Was the BBOT Form 4 transaction an open-market sale of shares?

No, it was not an open-market sale. The 343 BridgeBio Oncology Therapeutics shares were withheld by the company to pay COO Elmelech Idan’s tax withholding obligations when his restricted stock units vested.

How many BBOT shares were withheld from Elmelech Idan for taxes and at what price?

The company withheld 343 shares of BridgeBio Oncology Therapeutics common stock. The shares were valued at $7.80 each for this tax-withholding disposition related to the vesting of restricted stock units.

How many BridgeBio Oncology Therapeutics shares does Elmelech Idan hold after this Form 4 event?

Following the tax-withholding disposition, Elmelech Idan directly holds 14,495 shares of BridgeBio Oncology Therapeutics common stock. This reflects his remaining position after 343 shares were withheld to cover tax obligations.

What caused the tax-withholding disposition reported in BBOT’s Form 4 filing?

The disposition was triggered by the vesting of restricted stock units. To cover COO Elmelech Idan’s tax withholding obligations, BridgeBio Oncology Therapeutics withheld 343 shares of its common stock instead of requiring a separate cash payment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Elmelech Idan

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO & Principal Financial Ofcr

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		F		343(1)	D	$7.8	14,495	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

	/s/ Aaron Chan, Attorney-in-Fact	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)